Baird analyst Joel Beatty raised the firm’s price target on Sage Therapeutics (SAGE) to $9 from $7 and keeps a Neutral rating on the shares. The firm updated its target to reflect its proposed acquisition price.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- H.C. Wainwright sees potential competition for Sage from Biogen
- Sage Therapeutics price target raised to $9 from $8 at Truist
- Hold Rating on SAGE Therapeutics Amid Uncertainty and Acquisition Developments
- Sage Therapeutics price target raised to $8.50 from $8 at Canaccord
- Hold Rating on SAGE Therapeutics Amid Acquisition Offer and CVR Uncertainties